Semi-annual Performance Forecast for 2026
Securities code: 603139 Securities abbreviation: Kanghui Shares Announcement number: 2026-060 Shaanxi Kanghui Pharmaceutical Co., Ltd.
2026 Semi-annual Results Forecast
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
According to preliminary calculations by the financial department, Shaanxi Kanghui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is expected to achieve a net profit attributable to the owners of the parent company of approximately 11 million yuan in the first half of 2026, which will turn losses into profits compared with the same period last year.
During the reporting period, the company's non-recurring gains and losses affected an amount of approximately 35 million yuan. It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be approximately -24 million yuan in the first half of 2026.
1. Performance forecast for this period
(1) Performance forecast period
From January 1, 2026 to June 30, 2026.
(2) Performance forecast
According to preliminary calculations by the financial department, the company expects to achieve a net profit attributable to the owners of the parent company of about 11 million yuan in the first half of 2026, which will turn losses into profits compared with the same period last year.
It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be approximately -24 million yuan in the first half of 2026.
(3) This performance forecast is the company’s preliminary forecast based on its operating conditions and has not been audited by an accounting firm.
2. Half-year performance in 2025
(1) Total profit: -56.7932 million yuan. Net profit attributable to owners of parent company:
-40.2036 million yuan. Net profit attributable to owners of the parent company after deducting non-recurring gains and losses:
-42.8271 million yuan.
(2) Earnings per share: -0.40 yuan.
3. The main reason why this period’s performance turned losses into profits
During the reporting period, in order to improve the efficiency of asset use, the company disposed of some idle assets (a batch of computers and related equipment) and achieved a net profit of 43.29 million yuan. This income was a non-recurring profit and loss, which had a large positive impact on the company's performance for the current period.
During the reporting period, the company's wholly-owned subsidiary Beijing Kanghui Zhichuang Technology Co., Ltd. advanced its business in an orderly manner, and its revenue scale increased steadily, achieving a net profit of approximately 3.46 million yuan, effectively improving the company's current profit level.
During the reporting period, the internal integration of Jiangsu Huihe Digital Energy Technology Co., Ltd., the company's controlled subsidiary, was smoothly promoted, and its operation and management continued to be optimized, achieving a net profit of approximately 2.75 million yuan, which had a positive impact on the company's performance for the current period.
During the reporting period, affected by policy adjustments in the pharmaceutical industry and changes in the macroeconomic environment, the parent company's sales revenue declined significantly. For this reason, the company actively adjusted its sales strategy, increased investment in channel construction, brand building, etc., increased product investment agents and Internet sales, and further supplemented the declining sales of terminal products in the hospital. Although product sales were basically the same as the same period last year, due to different channels and product structures, the parent company suffered losses, which affected the performance of this period.
During the reporting period, the pre-reorganization application of the controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. (hereinafter referred to as "Shaanxi Youbang") was accepted by the court. It is in the stage of recruiting investors and has not yet entered the reorganization stage. Shaanxi Youbang's fixed asset depreciation and financing loan interest expenses are relatively large, resulting in Shaanxi Youbang still suffering a large loss in the first half of 2026, which affects the performance of this period.
At the end of 2025, the holding subsidiary Shaanxi New High-tech Pharmaceutical Co., Ltd. (hereinafter referred to as "New High-tech Pharmaceutical") stopped its pharmaceutical distribution-related business due to strategic adjustments, leaving only the house rental business. During the reporting period, due to business adjustments, new high-tech revenue dropped sharply and the amount of losses increased compared with the same period last year, which affected the company's current performance.
During the reporting period, the controlled subsidiary Sichuan Chunsheng Pharmaceutical Group Co., Ltd. continued to be affected by factors such as industry policies and price fluctuations of Chinese medicinal materials, and its operating performance continued to suffer losses (the loss was the same as the same period last year), which affected the company's current performance.
4. Risk warning
This performance estimate is a preliminary calculation based on the company's financial department's own professional judgment and has not yet been audited by a certified public accountant.
5. Other explanations
The above performance forecast data are only preliminary accounting data. The specific and accurate financial data shall be subject to the "2026 Semi-Annual Report" officially disclosed by the company. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Shaanxi Kanghui Pharmaceutical Co., Ltd. Board of Directors
July 15, 2026